The user has been using 1.25 mg of oral minoxidil and finasteride since September 2025 to address diffuse hair thinning, and is considering trying a new shampoo. Other users suggest increasing the minoxidil dose and trying dutasteride.
The user experienced severe side effects from finasteride, including panic attacks and suicidal thoughts, and is seeking alternative hair loss treatments. They have been using oral finasteride and topical minoxidil.
The user shared progress after two months using a topical formulation containing Dutasteride 0.25%, Minoxidil 5%, Cetirizine 1%, Melatonin 0.5%, Caffeine 2%, and Latanoprost 0.005%. The focus is on hair loss treatment results.
Pyrilutamide is an experimental hair loss treatment, with users discussing its availability and cost from sources like Anagen Inc, Actifolic, and MinoxidilMax. Some users express concerns about product authenticity and suggest waiting for further trial results to assess its safety and effectiveness.
The conversation is about whether Saw Palmetto, which has similar but less potent effects to Finasteride, could cause the same side effects due to lowering DHT levels. The user is considering oral Saw Palmetto as an alternative to Finasteride for hair loss treatment.
A 17-year-old is considering using saw palmetto for hair loss until they can get finasteride, while currently using minoxidil and ketoconazole. Users suggest that saw palmetto is weak, and recommend continuing minoxidil and ketoconazole until finasteride is available.
Zinc picolinate and saw palmetto may lower DHT but are less effective than finasteride. Finasteride and minoxidil are preferred treatments, with ketoconazole shampoo as a suggested addition.
Clascoterone 5% solution is not yet commercially available, with only the 1% solution currently sold for acne. Users discuss the potential of Clascoterone as a hair loss treatment, comparing it to other anti-androgens like RU58841 and Eucapil.
Oral minoxidil is causing significant blood pressure fluctuations and increased heart rate, leading the user to consider switching to topical minoxidil and tretinoin. The user plans to consult a cardiologist and is likely to stop using oral minoxidil.
Pyrilutamide, a potential hair loss treatment that has been tested in Phase 2 trials and may be available for purchase through a group buy in June. It is purported to have similar effects on hair growth as Dutasteride.
A 29-year-old experiencing slow hair loss is considering treatments like Fluridil, CB0301, and Pyrilutamide, and has been prescribed Minoxidil and Finasteride but prefers to avoid Finasteride. They are seeking advice on whether these treatments are worth trying.
Pyrilutamide/KX-826 is being considered as a potential treatment for female androgenetic alopecia (AGA), but its high cost and limited data on effectiveness are concerns. Kintor markets it for both men and women.
User is considering switching from finasteride to dutasteride and adding pyrilutamide for hair loss treatment. Other users recommend dutasteride for its effectiveness and suggest adding pyrilutamide.
A 24-year-old male with androgenetic alopecia is using a treatment of Dutasteride 0.5 mg, oral Minoxidil 2.5 mg, L-cysteine, and a Ketoconazole/Caffeine/CBD shampoo. He's considering using a dermaroller to improve results, taking biotin and iron vitamins, and quitting nicotine due to its potential link to hair loss.
The conversation discusses Kintor's initiation of a new Phase 3 trial to assess the long-term safety of Pyrilutamide (KX-826) for hair loss, which will last 52 weeks. Specific treatments mentioned include Pyrilutamide.
The user resumed taking 5mg oral minoxidil and 0.5mg dutasteride daily, with vitamins, and noticed hair regrowth. They switched from finasteride to dutasteride due to side effects and prefer oral minoxidil over topical for convenience and effectiveness.
RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.
Topical finasteride is currently more effective than pyrilutamide for hair loss. Combining treatments like topical finasteride and pyrilutamide may enhance results due to different mechanisms.
The safety of combining alfatradiol and fluridil with finasteride as a potential treatment for male pattern baldness, which is approved in the European Union. Other treatments such as minoxidil and RU58841 were also discussed.
Clascoterone cream can be used on the scalp, but it may not be effective due to its dosage. AR antagonists like clascoterone are generally less effective than 5AR inhibitors for hair loss.
Minoxidil caused water retention and gastrointestinal issues for the user, which improved after stopping the medication. The user is now using finasteride and topical minoxidil, experiencing excessive urination and concerns about systemic absorption.
Epristeride is a selective 5 alpha reductase type 2 inhibitor that may reduce scalp DHT similarly to finasteride, with potentially fewer side effects. It is suggested that combining epristeride with finasteride or dutasteride could enhance hair loss treatment effectiveness.
The user increased their steroid dosage and noticed hair shedding, so they adjusted their regimen by reducing steroid doses and adding oral dutasteride. They are also experimenting with combining RU-58841 and KX-826/pyrilutamide in minoxidil to address hair loss.
Tazarotene's potential to enhance Minoxidil conversion, similar to Tretinoin, is questioned. Users discuss the lack of information and seek further details.
The user stopped using Alfatradiol after 4 months due to no hair improvement and side effects like dry scalp and gallbladder pain. They are considering trying topilutamide, which is suggested as an alternative.